Skip to main content
News

Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta’s Rhenium-SCT

Garching, Munich. Germany – OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]).

These patients were treated on 8 April and are now part of 210 adults participating in the international study that will follow their progress over the next 24 months.

The EPIC-Skin study is being conducted through study centres located in Australia, Austria, Germany and the United Kingdom. Hosting multiple study centres in Australia, these Sydney patients follow the Gold Coast patients that were the first-globally to be treated as part of the study.

Dr Sam Vohra, Medical Director at OncoBeta Australia, says, “Rhenium-SCT can be applied directly to an affected area, without harming or scarring surrounding tissue. It is important we collect data through the EPIC-Skin Study to further validate the efficacy, safety and patient quality of life after treatment of NMSCs with Rhenium-SCT.”

There are more than 7.7 million cases of NMSC each year, and incidence rates are increasing globally. 1,2 Standard treatments for NMSCs are surgery-based approaches, which may have a risk of scarring or loss of function. Rhenium-SCT uses a paste containing ß-emitting particles that is applied directly to the lesion, which eliminate cancer cells in one single session† and without the need for surgery.3-5

The EPIC-Skin study will measure Patient Reported Outcomes such as quality of life, treatment comfort and cosmetic outcomes, as well as further evaluating the efficacy of Rhenium-SCT for the treatment of NMSC. To provide a simple and streamlined way to record their experiences, patients in the study will utilise OncoBeta’s Clinical Study app.

OncoBeta Australia Country Manager Ken Rikard-Bell says, “NMSC is a significant health concern both here in Australia and around the world. This study will offer new insights into the treatment of NMSC and the role of Rhenium-SCT® in the suite of treatments available to patients. It is exciting what this study could mean for the future of NMSC treatment.”

Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, “OncoBeta’s goal is to provide the best innovative solutions for patients suffering from NMSCs. The patient journey is sometimes a difficult one and as a healthcare service provider we are committed to making this journey as easy, effective and efficient as possible. The EPIC-Skin Study will be critical in assisting us in improving patient outcomes for those suffering from NMSCs.”

Back